VNU cancels IMS deal
This article was originally published in The Tan Sheet
Executive Summary
Dutch publishing company VNU has agreed to terminate the merger with IMS Health after nearly 50% of shareholders voiced opposition to the deal, the Haarlem, Netherlands-based firm announces Nov. 17. The deal would have needed approval from more than half of shareholders in order to go through, VNU explained. The company will pay a termination fee of $15 mil. to IMS due to the falling-through of the deal. VNU announced the $7 bil. merger plans in July, but vacillated on the acquisition during the week of Nov. 7 (1"The Tan Sheet" Nov. 14, 2005, In Brief)...
You may also be interested in...
IMS/VNU merger
VNU is considering amending or terminating its merger agreement with IMS Health, the company says Nov. 7. The two firms agreed to the $7 bil. merger in July and expected the deal to close in early 2006 (1"The Tan Sheet" July 18, 2003, p. 9). However, Netherlands-based VNU says "shareholders claiming to represent 48% of VNU's outstanding shares [said] they would not support the transaction under any circumstances." VNU is AC Nielsen's parent company and provides consumer, marketing and media information to the healthcare industry; IMS Health focuses primarily on Rx healthcare. "Various possible alternatives" have been discussed including the deal's revision, VNU says...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.